LAUSR

This systematic review and meta‐analysis were conducted to evaluate the impact of bergamot (KoksalGarry) and its nutraceutical compounds on lipid profiles. PubMed, Web of Knowledge, Scopus, and Google Scholar searched for relevant articles. Trials investigating the effect of oral bergamot supplementation on serum levels of total cholesterol (TC), triglyceride (TG), low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C) in adults were included. The mean differences and standard deviations were pooled using a random‐effects model. Fourteen trials were included in this systematic review and meta‐analysis. Bergamot supplementation significantly decreased serum levels of TC (weighted mean difference (WMD): −63.60 mg/dL; 95% CI: −78.03 to −49.18; p < .001), TG (WMD: −74.72 mg/dL; 95% CI: −83.58 to −65.87; p < .001), LDL‐C (WMD: −55.43 mg/dL; 95% CI: −67.26 to −43.60; p < .001), and increased HDL‐C (WMD: 5.78 mg/dL; 95% CI: 3.27 to 8.28; p < .001), respectively. Our systematic review of the effects of nutraceuticals containing bergamot on lipid markers showed inconsistent results. The results showed that bergamot supplementation might improve lipid profiles. The findings for nutraceutical compounds containing bergamot were inconsistent. However, the clinical efficacy of bergamot on lipid profiles needs to be further established through higher‐quality studies.